To evaluate retention of abatacept over 24 months in patients with rheumatoid arthritis (RA) in routine clinical practice across Europe and Canada.

Nüßlein, H.G., Alten, R., Galeazzi, M., Lorenz, H.M., Nurmohamed, M.T., Bensen, W.G., et al. (2016). Efficacy and prognostic factors of treatment retention with intravenous abatacept for rheumatoid arthritis: 24-month results from an international, prospective, real-world study. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 34(3), 489-499.

Efficacy and prognostic factors of treatment retention with intravenous abatacept for rheumatoid arthritis: 24-month results from an international, prospective, real-world study

GALEAZZI, MAURO;
2016-01-01

Abstract

To evaluate retention of abatacept over 24 months in patients with rheumatoid arthritis (RA) in routine clinical practice across Europe and Canada.
2016
Nüßlein, H.G., Alten, R., Galeazzi, M., Lorenz, H.M., Nurmohamed, M.T., Bensen, W.G., et al. (2016). Efficacy and prognostic factors of treatment retention with intravenous abatacept for rheumatoid arthritis: 24-month results from an international, prospective, real-world study. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 34(3), 489-499.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/996406
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo